ResultsIQ

ResultsIQ › Latest results › Global Health Limited

Global Health Limited Q1 FY26 results press release summary

NSE: MEDANTA · BSE: 543654

Results press release of 7 Aug 2025, summarised by AI from the filing.

110-bed Ranchi hospital operationalized in July 2025, expanding regional presence in underserved market.

Key takeaways

  1. Ranchi operational 110-bed Ranchi hospital operationalized in July 2025, expanding regional presence in underserved market.
  2. Growth drivers Increased patient volumes and improved realizations, with consistent growth across mature hospitals as well as Lucknow and Patna hospital.
  3. Risk Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially.

Original filing on BSE

Global Health Limited Q1 FY27 results

As filed: Revenue ₹1,304 cr (+26% year on year), EBITDA ₹287 cr (+26% year on year), PAT ₹157 cr (−1% year on year), EBITDA margin 22.0% (−3 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹1,159 cr (+25% year on year), EBITDA ₹244 cr (+9% year on year), PAT ₹142 cr (+40% year on year), EBITDA margin 21.0% (−303 bps). Score 67 of 100, Above trend. Revenue and profit growth were well above the company's own trend; EBITDA growth was in line with it. EBITDA margin fell 303 bps year on year. Share price after the results: +1.9% in 29 days (Nifty 500: −0.1%).
  • Q3 FY26: Revenue ₹1,121 cr (+19% year on year), EBITDA ₹217 cr (−8% year on year), PAT ₹95.0 cr (−17% year on year), EBITDA margin 19.4% (−575 bps). Score 34 of 100, Below trend. Revenue growth was above the company's own trend; EBITDA and profit before exceptional items growth were well below it. EBITDA margin fell 575 bps year on year. Profit fell 15% from last quarter. Revenue rose ₹178 cr on a year ago, more than the ₹110 cr it added the year before. Share price after the results: −1.1% in 30 days (Nifty 500: −4.5%).
  • Q2 FY26: Revenue ₹1,099 cr (+15% year on year), EBITDA ₹231 cr (+1% year on year), PAT ₹158 cr (+21% year on year), EBITDA margin 21.0% (−281 bps). Score 42 of 100, In line with trend. Revenue and profit growth were in line with the company's own trend; EBITDA growth was well below it. EBITDA margin fell 281 bps year on year. Revenue rose ₹142 cr on a year ago, more than the ₹113 cr it added the year before. Share price after the results: −7.1% in 28 days (Nifty 500: +1.3%).
  • Q1 FY26: Revenue ₹1,031 cr (+20% year on year), EBITDA ₹227 cr (+21% year on year), PAT ₹159 cr (+50% year on year), EBITDA margin 22.0% (+30 bps). Score 75 of 100, Above trend. Revenue and profit growth were well above the company's own trend; EBITDA growth was above it. EBITDA margin rose 30 bps year on year. Revenue rose ₹170 cr on a year ago, more than the ₹88.0 cr it added the year before. Share price after the results: +6.1% in 29 days (Nifty 500: +0.6%).
  • Q4 FY25: Revenue ₹931 cr (+15% year on year), EBITDA ₹224 cr (+25% year on year), PAT ₹101 cr (+28% year on year), EBITDA margin 24.1% (+193 bps). Score 67 of 100, Above trend. Revenue growth was in line with the company's own trend; EBITDA growth was well above it; profit before exceptional items growth was above it. EBITDA margin rose 193 bps year on year. Profit fell 3% from last quarter. Revenue rose ₹122 cr on a year ago, more than the ₹106 cr it added the year before. Share price after the results: −4.6% in 29 days (Nifty 500: +0.5%).
  • Q3 FY25: Revenue ₹943 cr (+13% year on year), EBITDA ₹237 cr (+12% year on year), PAT ₹143 cr (+15% year on year), EBITDA margin 25.1% (−32 bps). Score 44 of 100, In line with trend. Revenue growth was below the company's own trend; EBITDA and profit growth were in line with it. EBITDA margin fell 32 bps year on year.
  • Q2 FY25: Revenue ₹957 cr (+13% year on year), EBITDA ₹228 cr (+7% year on year), PAT ₹131 cr (+5% year on year), EBITDA margin 23.8% (−141 bps). Score 44 of 100, In line with trend. EBITDA margin fell 141 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Global Health Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.